Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tozinameran + riltozinameran (Pfizer)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Tozinameran + riltozinameran is a bivalent mRNA vaccine developed by Pfizer and BioNTech to provide protection against COVID-19. It consists of two messenger RNA (mRNA) components: tozinameran, which encodes the spike protein of the original SARS-CoV-2 strain (Wuhan-Hu-1), and riltozinameran, which encodes the spike protein of the Omicron BA.4 and BA.5 variants. The vaccine utilizes a lipid nanoparticle (LNP) delivery system to transport the mRNA into host cells, where it is translated into spike proteins that elicit a robust immune response, including the production of neutralizing antibodies and T-cell activation. In the context of clinical development by Cellid Co., Ltd., this bivalent vaccine serves as the active comparator in Phase 3 trials evaluating the immunogenicity and safety of the investigational adenovirus-vector vaccine AdCLD-CoV19-1 OMI.
- Brand names
- Comirnaty BivalentComirnaty Original/Omicron BA.4-5
- Other names
- tozinameran and riltozinameranPfizer-BioNTech COVID-19 Vaccine Bivalent
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on tozinameran + riltozinameran (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tozinameran + riltozinameran (Pfizer).